Table 1.
Single protein and RCR antigen combination dose assignments.
| Cohort | Formulation | RH5.1, µg | CyRPA, µg | Ripr, µg |
|---|---|---|---|---|
| 1 | RH5.1 + DPX | 1 | 0 | 0 |
| 2 | CyRPA + DPX | 0 | 1 | 0 |
| 3 | Ripr + DPX | 0 | 0 | 1 |
| 4 | RH5.1 + Ripr + DPX | 1 | 0 | 1 |
| 5 | RH5.1 + CyRPA + DPX | 1 | 1 | 0 |
| 6 | Ripr + CyRPA +DPX | 0 | 1 | 1 |
| * 7 | RH5.1 + Ripr + CyRPA + DPX (Equimolar Ratio) | 0.84* | 0.55* | 1.75* |
| 8 | RH5.1 + Ripr + CyRPA + DPX (Mass) | 1 | 1 | 1 |
| 9 | Adjuvant Alone (DPX; Negative Control) | 0 | 0 | 0 |
*Cohort #7 dose amounts (µg) are based on 14 pmole per antigen; the total protein dose per animal in Cohort #7 was 3.14 µg. MW of RH5.1, CyRPA and Ripr are 60,219, 39,470 and 124,840 g/mole, respectively.
In cohorts 7 & 8, antigen combinations were in RCR complex form prior to formulation with DPX.